Abstract:GLP-1 (glucagon-like peptide 1) and its mimetic exendin-4 are used against Type 2 diabetes. C-peptide has also proven promising to enhance insulin action. Since insulin secretion in vivo can be rapidly tuned by changes in islet microcirculation, we evaluated the influence of GLP-1, exendin-4 and C-peptide on pancreatic IBF (islet blood flow), and dynamic changes in insulin secretion and glycaemia in the rat. Adult male Wistar rats were divided into four groups given intravenous saline, GLP-1, exendin-4 or C-peptide respectively and administered either saline or 30% glucose. Furthermore, we investigated the effect of intravenous infusion of different doses of exendin-4 into either the femoral vein or the portal vein on islet microcirculation. A non-radioactive microsphere technique was adopted to measure the regional blood flow. Both GLP-1 and exendin-4 prevented the glucose-induced PBF (pancreatic blood flow) redistribution into the islets. Infusion of exendin-4 into the portal vein did not alter pancreatic islet microcirculation, while infusion of exendin-4 into femoral vein significantly decreased basal IBF. C-peptide increased basal IBF and the proportion of IBF out of total PBF, but did not affect the islet microcirculation after glucose administration. GLP-1, exendin-4 and C-peptide stimulated insulin secretion and significantly decreased glycaemia. Blocking NO formation did not prevent the decreased IBF and post-load glycaemia evoked by exendin-4, but further decreased IBF and KBF (kidney blood flow) and increased basal glycaemia. Blocking the vagus nerve enhanced pancreatic IBF and further decreased post-load glycaemia and KBF and increased basal glycaemia. The vascular modulatory effect on pancreatic islet microcirculation described herein, with subsequent effects on in vivo insulin secretion and glycaemia, might be one of the mechanisms underlying the anti-diabetic actions of GLP-1 and its long acting mimetic exendin-4, as well as that of C-peptide.

Protective effects of glucagon-like polypeptide 1(GLP-1),GLP-1 mimetics and dipeptidyl peptidase IV on pancreatic function

Dipeptidyl Peptidase IV(DPP IV): a Novel Emerging Target for the Treatment of Type 2 Diabetes

GLP1-derived nonapeptide GLP1(28-36)amide protects pancreatic β-cells from glucolipotoxicity

Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells

Progress of extrapancreatic effects by glucagon-like peptide-1

The Plight of China's Islet Function in Patients with Diabetes and the Way Out

Research Progress of Glucagon-Like Peptide-1 in the Treatment of Type 2 Diabetes Mellitus

New anti-diabetic agents-DPP-4 inhibitors: Viewing the advance of treatment for T2DM from pancreatic α-cells

Glp-1, Exendin-4 and C-Peptide Regulate Pancreatic Islet Microcirculation, Insulin Secretion and Glucose Tolerance in Rats

Emerging Roles of Dipeptidyl Peptidase-4 Inhibitors in Delaying the Progression of Type 1 Diabetes Mellitus

New insight into the mechanisms underlying the function of the incretin hormone glucagon-like peptide-1 in pancreatic β-cells: the involvement of the Wnt signaling pathway effector β-catenin

Cardiovascular protective effects of glucagon-like peptide-1 agents in patients with type 2 diabetes

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

Research Progress in the Effect Evaluation of GLP1-1 Agonists

Hepatic function of glucagon-like peptide-1 and its based diabetes drugs

Favorable Effects of GLP-1 Receptor Agonist against Pancreatic β-Cell Glucose Toxicity and the Development of Arteriosclerosis: “The Earlier, the Better” in Therapy with Incretin-Based Medicine

The Mechanism of the Action of Dipeptidyl Peptidase-4 Inhibitors and Its Use in Type 2 Diabetes

Pleiotropic Benefits of DPP-4 Inhibitors Beyond Glycemic Control

Combination of GLP-1 Receptor Activation and Glucagon Blockage Promotes Pancreatic Β-Cell Regeneration in Situ in Type 1 Diabetic Mice

Protective mechanism of GLP-1 on kidney in diabetic kidney disease patients

Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass